Results from the Phase III ABTECT-1 (NCT05507203) and ABTECT-2 (NCT05507216) trials showed that Abivax’s obefazimod demonstrated significant clinical remission in patients with ulcerative colitis.

While monsoon sees an uptick in cases, declining gut health is otherwise becoming a perennial problem. Here’s what research ...